CP Liver/Bile Ducts


The interdisciplinary Liver Cancer Center Heidelberg (LCCH) incorporates all relevant disciplines and provides excellent patient care. The LCCH promotes innovative clinical trials, including heavy ion treatment and the world’s first HCC umbrella trial to use molecular stratification for trial allocation. The Liver Pathology Center assesses more than 4000 cases per year forming the basis of a strong portfolio of funded program project grants, including the SFB/TRR77 ‘Liver Cancer’ as the largest European HCC research consortium.

CP Liver/Bile Ducts


Prof. Dr. Dr. Springfeld

Prof. Dr. Dr. Springfeld
Medical Oncology


Scientific Goals

  • Molecular mechanisms of liver cancer and targeted treatment (SFB/TRR77): (1) HCV persistence (Ruggieri Cell Host Microbe 2012; Bauhofer Gastroenterology 2012), (2) metabolic dysfunction (Eichelbaum Nat Biotechnol 2012), (3) chronic hepatic inflammation (Pusterla Hepatology 2013), (4) key signaling pathways (Singer Mol Cell 2012; Neumann Hepatology 2012; Kang Nature 2011; Tschaharganeh Gastroenterology 2013), (5) high-throughput in vivo screening (Wuestefeld Cell 2013).
  • Molecular diagnostic algorithms in HCC (Schirmacher Gastroenterology 2013).
  • Comprehensive mechanism-based trial program that includes biomarker development.
  1. Wuestefeld T, Pesic M, Longerich T, Kang TW, Yevsa T, Dauch D, Potapova A, Rittelmeier I, Jarke M, Geffers R, Scharfe M, Klawonn F, Malek NP, Schirmacher P, Ott M, Vogel A, Manns MP, Zender L. A direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell 2013; 153(2):389-401 (IF 32,4)
  2. Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, Ladu S, Singer S, Pinna F, Gretz N, Sticht C, Tomasi ML, Delogu S, Evert M, Fan B, Ribback S, Jiang L, Brozzetti S, Bergmann F, Dombrowski F, Schirmacher P, Calvisi DF, Breuhahn K. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology. 2013 Jun;144(7):1530-1542 (IF 2012 11,675)
  3. Bauhofer O, Ruggieri A, Schmid B, Schirmacher P, Bartenschlager R. Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response. Gastroenterology 2012; 143(2):429-382 (IF 2012 11,675)
  4. Singer S, Zhao R, Barsotti AM, Ouwehand A, Fazollahi M, Coutavas E, Breuhahn K, Neumann O, Longerich T, Pusterla T, Powers MA, Giles KM, Leedman PJ, Hess J, Grunwald D, Bussemaker HJ, Singer RH, Schirmacher P, Prives C. Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. Mol Cell 2012;48(5):799-810 (IF 14,18)
  5. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwalder M, Khan S, Gil J, Bruder D, Manns M, Schirmacher P, Tacke F, Ott M. Luedde T, Longerich T, Kubicka S, Zender L. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011; 479(7374):547-51 (IF 36,3)